$384 Million is the total value of DAFNA Capital Management LLC's 94 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | New | SPDR SP BIOTECH ETFetf | $24,223,000 | – | 269,500 | +100.0% | 6.31% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $4,773,000 | – | 93,935 | +100.0% | 1.24% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $3,511,000 | – | 42,700 | +100.0% | 0.92% | – |
| EWTX | New | EDGEWISE THERAPEUTICS INC | $3,460,000 | – | 356,750 | +100.0% | 0.90% | – |
| BCYC | New | BICYCLE THERAPEUTICS PLCsponsored ads | $2,334,000 | – | 53,200 | +100.0% | 0.61% | – |
| AUTL | New | AUTOLUS THERAPEUTICS PLCspon ads | $2,069,000 | – | 496,150 | +100.0% | 0.54% | – |
| New | DICE THERAPEUTICS INC | $1,798,000 | – | 94,000 | +100.0% | 0.47% | – | |
| IMCR | New | IMMUNOCORE HOLDINGS PLCads | $1,611,000 | – | 53,878 | +100.0% | 0.42% | – |
| GHRS | New | GH RESEARCH PLCordinary shares | $1,006,000 | – | 55,000 | +100.0% | 0.26% | – |
| CMPS | New | COMPASS PATHWAYS PLCsponsored ads | $965,000 | – | 74,890 | +100.0% | 0.25% | – |
| New | VIGIL NEUROSCIENCE INC | $701,000 | – | 99,754 | +100.0% | 0.18% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.